Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
04/2003
04/03/2003WO2003027319A1 Aptamers containing sequences of nucleic acids or nucleic acid analogues bound homologously, or in novel complexes
04/03/2003WO2003027316A2 Methods of using 33751, a human potassium channel family member
04/03/2003WO2003027271A2 Regulation of adenovirus dna packaging by iptg
04/03/2003WO2003027269A1 Chronic pathogen-expressing cell lines
04/03/2003WO2003027266A2 Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
04/03/2003WO2003027251A2 Novel molecules of the pyrin domain protein family and uses thereof
04/03/2003WO2003027246A2 Antagonists
04/03/2003WO2003027143A2 Gene and protein relating to hepatocellular carcinoma
04/03/2003WO2003026696A1 Method of controlling proliferation of cancer cells and cell death
04/03/2003WO2003026691A2 Use of hmgb1 for the activation of dendritic cells
04/03/2003WO2003026674A1 Coadministration of transport protein with conjugated cobalamin to deliver agents
04/03/2003WO2003026584A2 Stem cells of the islets of langerhans and their use in treating diabetes mellitus
04/03/2003WO2003026579A2 Combination therapies for immune mediated diseases
04/03/2003WO2003026566A2 Atlastin
04/03/2003WO2003026492A2 Prevention and treatment of restenosis by local administration of drug
04/03/2003WO2003006104A3 Lymphatic endothelial cells materials and methods
04/03/2003WO2002099052A3 Opns as modifiers of the p53 pathway and methods of use
04/03/2003WO2002099051A3 Nits as modifiers of the p53 pathway and methods of use
04/03/2003WO2002092016A3 Therapeutic use of rank antagonists
04/03/2003WO2002088336A3 Genetically modified yt cell line and use thereof
04/03/2003WO2002070559A3 Nuclear hormone receptor ligand binding domains
04/03/2003WO2002068465A3 Novel p53-inducible protein
04/03/2003WO2002059256A3 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
04/03/2003WO2002057294A3 Zinc finger proteins for dna binding and gene regulation in plants
04/03/2003WO2002044419A3 Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
04/03/2003WO2002024909A9 Receptor nucleic acids and polypeptides
04/03/2003WO2002022174A9 A novel cationic lipopolymer as biocompatible gene delivery agent
04/03/2003WO2002017852A3 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
04/03/2003WO2002014526A3 Replication competent aav helper functions
04/03/2003WO2002012524A3 Adenovirus e1b-55k single amino acid mutants and methods of use
04/03/2003WO2002010357A3 Gsk3 polypeptides
04/03/2003WO2002010214A3 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
04/03/2003US20030066097 Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
04/03/2003US20030065160 Secreted protein HEMAE80
04/03/2003US20030065151 Secreted protein HCEJQ69
04/03/2003US20030065140 Novel proteins and nucleic acids encoding same
04/03/2003US20030065033 Lipid derivatives of polythiourea
04/03/2003US20030064958 Pharmaceutical compositions and methods relating to fucans
04/03/2003US20030064953 Transferring genes; muscular disorders
04/03/2003US20030064952 Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
04/03/2003US20030064950 Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity
04/03/2003US20030064949 Anticancer agents
04/03/2003US20030064944 Controlling cell differentiation, cell proliferation
04/03/2003US20030064926 Angiostatin fragments and method of use
04/03/2003US20030064919 Novel polypeptides and polynucleotides encoding same
04/03/2003US20030064917 Methods and compositions for inhibiting angiogenesis
04/03/2003US20030064517 Expression vectors, transfection systems, and method of use thereof
04/03/2003US20030064510 Prevention or delaying apoptosis in recombinant cell; obtainceks transforme with nucleotide sequences coding antiapoptotic agents, express sequences, monitor adjustment in apotosis activity
04/03/2003US20030064509 Novel chromosomal vectors and uses thereof
04/03/2003US20030064503 Device
04/03/2003US20030064492 Nucleotide sequences for use as tool in human therapeutics and diagnostics
04/03/2003US20030064490 Nucleotide sequences coding polypeptide for use as therapeutic, diagnostic, nutritional and cosmetic tools
04/03/2003US20030064479 Helical cytokine zalpha33
04/03/2003US20030064439 Nucleotide sequences coding polypeptide for use in the treatment of schizophrenia and alzheimer's diseases
04/03/2003US20030064418 Protein for use in the diagnosis and treatment of cancer
04/03/2003US20030064407 Secreted and transmembrane polypeptides and nucleic acids encoding the same
04/03/2003US20030064385 Genes expressed in breast cancer as prognostic and therapeutic targets
04/03/2003US20030064384 Beta-catenin is a strong and independent prognostic factor for cancer
04/03/2003US20030064383 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cancer
04/03/2003US20030064378 Compositions and methods relating to lung specific genes and proteins
04/03/2003US20030064374 Detecting neuronal stress in humans; obtain sample, measure phosphodiesterase concentration, evaluate for neuronal stress
04/03/2003US20030064369 Novel proteins and nucleic acids encoding same
04/03/2003US20030064088 Surgically implantable and sealable drug delivery device that upon contact of its contents via an interface window or port with an organ or tissue exposes a therapeutic agent to organ or tissue surface, allowing a controlled, selective diffusion
04/03/2003US20030064074 Recombinant gelatins in vaccines
04/03/2003US20030064072 For diagnosis, therapy and prophylaxis of disorders related to the lung, including lung cancer
04/03/2003US20030064063 For prophylaxis of type I hypersensitivity disease in a subject receiving immunotherapy
04/03/2003US20030064059 Embryonic stem cells, clinical applications and methods for expanding in vitro
04/03/2003US20030064057 Administering hematopoietic stem cells to the patient via intravenous injection; administering neuronal stem cells to the patient via subcutaneous injection for improving athletic performance and increasing lean muscle mass in a patient
04/03/2003US20030064054 Detection of human immunodeficiency virus using cells transduced with a complex viral vector
04/03/2003US20030064022 Labeling human embryonic stem cells with a biocompatible label; administering labeled embryonic stem cells to patient via intravenous injection; detecting labeled embryonic stem cells to thereby identify the region of disease state
04/03/2003CA2820170A1 Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
04/03/2003CA2461861A1 Stem cells of the islets of langerhans and their use in treating diabetes mellitus
04/03/2003CA2461705A1 Coadministration of transport protein with conjugated cobalamin to deliver agents
04/03/2003CA2461666A1 Combination therapies for immune mediated diseases
04/03/2003CA2461526A1 Aptamers containing sequences of nucleic acids or nucleic acid analogues bound homologously, or in novel complexes
04/03/2003CA2461410A1 Dna providing system
04/03/2003CA2461091A1 Use of hmgb1 for the activation of dendritic cells
04/03/2003CA2460787A1 Prevention and treatment of restenosis by local administration of drug
04/03/2003CA2459999A1 Antagonists_and agonists of igf-1 receptor
04/03/2003CA2459807A1 Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
04/02/2003EP1298220A1 Single nucleotide polymorphisms predicting cardiovascular disease
04/02/2003EP1298208A2 Ribozymes targeting a hiv tat sequence
04/02/2003EP1298203A2 Diagnosis and treatment of autoimmune diseases
04/02/2003EP1298202A2 Biological factors and neural stem cells
04/02/2003EP1298144A2 Murine monoclonal anti-idiotype antibody 3H1
04/02/2003EP1297852A1 Virus vector for introducing gene into renal cells
04/02/2003EP1297841A1 Pancreatic langerhans beta cell proliferation promoter and apoptosis inhibitor, and screening of candidate compounds for the e drugs
04/02/2003EP1297169A2 Method for transfecting cells using a magnetic field
04/02/2003EP1297168A2 Expression vectors
04/02/2003EP1297167A1 Tumour-cell specific gene expression and its use in cancer therapy
04/02/2003EP1297161A2 Methods and means for regulation of gene expression
04/02/2003EP1297147A2 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
04/02/2003EP1297139A2 G-protein coupled receptor org10
04/02/2003EP1297135A2 Pd-l2 molecules: novel pd-1 ligands and uses therefor
04/02/2003EP1297133A2 Gp354 nucleic acids and polypeptides
04/02/2003EP1297130A2 G-protein coupled receptors
04/02/2003EP1297129A2 Card domain containing polypeptides, encoding nucleic acids, and methods of use
04/02/2003EP1297122A2 Targeted chromosomal genomic alterations in plants using modified single stranded oligonucleotides
04/02/2003EP1297120A2 Liver-specific gene expression cassettes, and methods of use
04/02/2003EP1297119A2 Method for introducing nucleic acids and other biologically active molecules into the nucleus of higher eukaryotic cells by means of an electrical current
1 ... 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 ... 870